Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 1/20 | 0.43 |
| ▸ | SYK | P43405 | 7/20 | 0.42 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.38 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.37 |
| ▸ | LOX | P28300 | 1/20 | 0.37 |
| ▸ | IDH1 | O75874 | 3/20 | 0.36 |
| ▸ | HTR2C | P28335 | 3/20 | 0.36 |
| ▸ | HTR2A | P28223 | 2/20 | 0.36 |
| ▸ | HTR2B | P41595 | 2/20 | 0.36 |
| ▸ | IDH2 | P48735 | 2/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL171691 | 0.77 | ADRB1 (0.43) | ADRB1SYKLOXL2TAS2R14LOX | |
| SCHEMBL28872199 | 0.77 | SYK (0.38) | SYK | |
| SCHEMBL27285543 | 0.74 | ADRB1 (0.44) | ADRB1SYKLOXL2TAS2R14LOX | |
| SCHEMBL3295825 | 0.74 | MALT1 (0.47) | ADRB1SYKLOXL2TAS2R14LOX | |
| SCHEMBL17049228 | 0.73 | ADRB1 (0.43) | ADRB1SYKLOXL2TAS2R14LOX | |
| SCHEMBL345262 | 0.73 | HSP90AA1 (0.45) | ADRB1SYKLOXL2LOX | |
| SCHEMBL4428210 | 0.73 | ADRB1 (0.43) | ADRB1SYKLOXL2TAS2R14LOX | |
| SCHEMBL2873952 | 0.73 | ADRB1 (0.43) | ADRB1SYKLOXL2TAS2R14LOX | |
| SCHEMBL17959 | 0.73 | GABRA1 (0.50) | ADRB1SYKLOXL2TAS2R14LOX | |
| SCHEMBL1968808 | 0.73 | ADRB1 (0.43) | ADRB1SYKLOXL2TAS2R14LOX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117659017-B | TRPML1/2 modulator compound, pharmaceutical composition, preparation method and application thereof | 北京华益健康药物研究中心 | 2026-05-15 | — | — | CN | disclosed |
| WO-2026041663-A1 | P2X7 RECEPTOR ANTAGONISTS | BREYE THERAPEUTICS APS (DK) | 2026-02-26 | — | — | WO | disclosed |
| EP-4648853-A1 | TARGETED DEGRADATION OF VAV1 | Monte Rosa Therapeutics AG (CH) | 2025-11-19 | — | — | EP | disclosed |
| US-20250257075-A1 | MACROCYCLIC INHIBITORS OF KRAS FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2025-08-14 | — | — | US | disclosed |
| US-20250236617-A1 | BICYCLIC TETRAHYDROTHIAZEPINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2025-07-24 | — | — | US | disclosed |
| US-20250205219-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS AG (CH) | 2025-06-26 | — | — | US | disclosed |
| EP-4061813-B1 | PYRROLIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2025-06-04 | — | — | EP | disclosed |
| EP-4551578-A1 | MACROCYCLIC INHIBITORS OF KRAS FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2025-05-14 | — | — | EP | disclosed |
| WO-2025095751-A1 | NOVEL COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF CANCER COMPRISING SAME | 현대약품 주식회사 | 2025-05-08 | — | — | WO | disclosed |
| US-12257247-B2 | Targeted degradation of VAV1 | MONTE ROSA THERAPEUTICS AG (CH) | 2025-03-25 | — | — | US | disclosed |
| US-20130143895-A1 | BICYCLIC COMPOUNDS AND THEIR USES AS DUAL C-SRC / JAK INHIBITORS | DEBIOPHARM S.A. (CH) | 2013-06-06 | — | — | US | disclosed |
| US-8440679-B2 | Bicyclic compounds and their uses as dual c-SRC / JAK inhibitors | DEBIOPHARM S.A. (CH) | 2013-05-14 | — | — | US | disclosed |
| US-8440679-B2 | Bicyclic compounds and their uses as dual c-SRC / JAK inhibitors | DEBIOPHARM S.A. (CH) | 2013-05-14 | — | — | US | disclosed |
| US-20130012518-A1 | BICYCLIC COMPOUNDS AND THEIR USES AS DUAL C-SRC / JAK INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LTD. (IN) | 2013-01-10 | — | — | US | disclosed |
| US-20130012518-A1 | BICYCLIC COMPOUNDS AND THEIR USES AS DUAL C-SRC / JAK INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LTD. (IN) | 2013-01-10 | — | — | US | disclosed |
| US-20120208791-A1 | IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2012-08-16 | — | — | US | disclosed |
| WO-2011149995-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA [C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2011-12-01 | — | — | WO | disclosed |
| US-20110281870-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2011-11-17 | — | — | US | disclosed |
| WO-2011101806-A1 | BICYCLIC COMPOUNDS AND THEIR USES AS DUAL C-SRC / JAK INHIBITORS | DEBIOPHARM S.A. (CH) | 2011-08-25 | — | — | WO | disclosed |
| CN-1066175-C | Reactive dyes, their preparation and their use | CIBA SC HOLDING AG (CH) | 2001-05-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012518-A1 | BICYCLIC COMPOUNDS AND THEIR USES AS DUAL C-SRC / JAK INHIBITORS | JAK2, SRC, JAK1 | ADRB1 4048/4885SYK 30/4885LOXL2 3357/4885 |
| US-20120208791-A1 | IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | ABL1, ERBB2, RET | ADRB1 877/4885SYK 75/4885LOXL2 3679/4885 |
| US-12257247-B2 | Targeted degradation of VAV1 | VAV1, KRAS, CBL | ADRB1 3055/4885SYK 400/4885LOXL2 711/4885 |
| US-20110281870-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | CACNA1C, ORAI1, CACNA1S | ADRB1 163/4885SYK 2438/4885LOXL2 679/4885 |
| US-20250257075-A1 | MACROCYCLIC INHIBITORS OF KRAS FOR THE TREATMENT OF CANCER | KRAS, NRAS, HRAS | ADRB1 2427/4885SYK 2497/4885LOXL2 4617/4885 |
| US-20250236617-A1 | BICYCLIC TETRAHYDROTHIAZEPINE DERIVATIVES | GRIN2C, CYP3A4, BICRA | ADRB1 158/4885SYK 4400/4885LOXL2 4110/4885 |
| US-20250205219-A1 | TARGETED DEGRADATION OF VAV1 | VAV1, KRAS, CBL | ADRB1 3055/4885SYK 400/4885LOXL2 711/4885 |
| US-20130143895-A1 | BICYCLIC COMPOUNDS AND THEIR USES AS DUAL C-SRC / JAK INHIBITORS | JAK2, SRC, JAK1 | ADRB1 4048/4885SYK 30/4885LOXL2 3357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.